Akari Therapeutics (NASDAQ:AKTX) Earns Sell Rating from Analysts at StockNews.com
StockNews.com started coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Free Report) in a research report sent to investors on Monday. The brokerage issued a sell rating on the biopharmaceutical company’s stock. Akari Therapeutics Price Performance Akari Therapeutics stock opened at $3.60 on Monday. Akari Therapeutics has a twelve month low of $2.81 and a […]
More Stories
Icelandic Government Seeks to Hold Referendum in August on Restarting EU Accession Talks
By Victoria Friedman The Icelandic government has proposed holding a referendum on Aug. 29 on whether to restart accession talks...
Plaintiff Rests, Defense Begins Presenting Evidence in Social Media Addiction Trial
By Beige Luciano-Adams LOS ANGELES—After four weeks, attorneys representing the plaintiff in a landmark jury trial in Los Angeles Superior...
Trump Announces Military Coalition With Latin American Leaders to Eradicate Cartels
By Emel Akan and T.J. Muscaro DORAL, Fla.—U.S. President Donald Trump on March 7 welcomed his Latin American allies to...
Wall Street Review: Stocks Sell Off on Soaring Oil, Higher Yields
By Panos Mourdoukoutas Stocks moved lower this week as surging oil prices and rising bond yields weighed on investor sentiment....
Is The Trailer For Beef Season 2 out? Release Date, Cast, and Spoilers
After the tremendous success of Beef Season 1, all eyes were on Netflix for the official announcement of the renewal...
Bass x Machina: Release Date, Cast, Trailer, and Expected Plot
Good news for anime fans, Netflix has announced the release date of a new animated series, Bass x Machina. You...